Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12440428 | 0.88 | GPR119 (0.47) | ALDH1A1HPGDKDM4EGLARECQL | |
| SCHEMBL12440418 | 0.88 | GPR119 (0.47) | ALDH1A1HPGDKDM4EGLARECQL | |
| SCHEMBL1118269 | 0.85 | GPR119 (0.47) | ALDH1A1HPGDKDM4EGLARECQL | |
| SCHEMBL12003104 | 0.84 | NR1H2 (0.49) | ALDH1A1HPGDKDM4EGLARECQL | |
| SCHEMBL28230821 | 0.82 | GPR119 (0.53) | KDM4EGPR119TRPV3 | |
| SCHEMBL30730320 | 0.81 | ALDH1A1 (0.58) | ALDH1A1HPGDHSD17B10SMN1; SMN2TDP1 | |
| SCHEMBL30926340 | 0.81 | GPR119 (0.56) | ALDH1A1KDM4EGPR119TRPV3 | |
| SCHEMBL5279488 | 0.80 | ALDH1A1 (0.57) | ALDH1A1HPGDHSD17B10SMN1; SMN2TDP1 | |
| SCHEMBL1118237 | 0.79 | GPR119 (0.52) | KDM4EGPR119TRPV3JAK2JAK1 | |
| SCHEMBL18764600 | 0.79 | NR1H2 (0.50) | ALDH1A1HPGDKDM4EGLARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110177055-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2011-07-21 | — | — | US | disclosed |
| US-20110177055-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2011-07-21 | — | — | US | disclosed |
| US-7939547-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2011-05-10 | — | — | US | disclosed |
| US-7939547-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2011-05-10 | — | — | US | disclosed |
| US-20070276002-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
| US-20070276002-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276002-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | PRSS1, PRSS8, PRSS2 | ALDH1A1 3792/4885HPGD 922/4885KDM4E 4550/4885 |
| US-20110177055-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | PRSS1, PRSS8, PRSS2 | ALDH1A1 3828/4885HPGD 970/4885KDM4E 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.